Proteomics studies of neurotoxic amyloid β oligomers using size exclusion chromatography by Das, Anuj Kumer
1	  
	  
	  
	  
	  
Proteomics studies of neurotoxic amyloid β 
oligomers using size exclusion 
chromatography 
 
Anuj	  Kumer	  Das	  
	  
	  
	  
	  
	  
	  
	  
	  
Master’s	  thesis.	  30	  hec.	  Second	  cycle,	  A2E	  
Biotechnology-­‐	  Master’s	  programme	  
Uppsala	  2012	  
Independent	  Project	  in	  Biology,	  Department	  of	  Molecular	  Biology,	  2012.	  
	  	  	  	  	  	  Department	  of	  Molecular	  Biology	  
2	  
	  
Proteomics	  studies	  of	  neurotoxic	  amyloid	  β	  oligomers	  using	  size	  
exclusion	  chromatography	  
Anuj	  Kumer	  Das	  
	  
Supervisor:	  	  Dr.	  Christofer	  Lendel,	  Department	  of	  Molecular	  Biology,	  Swedish	  University	  of	  
Agricultural	  Sciences	  (SLU)	  
	  
Examiner:	  Dr.	  Jerry	  Ståhlberg,	  Department	  of	  Molecular	  Biology,	  Swedish	  University	  of	  
Agricultural	  Sciences	  (SLU)	  
	  
Credits:	  30	  
Level:	  Second	  cycle,	  A2E	  
Course	  title:	  Independent	  Project	  in	  Biology	  
Course	  code:	  EX0565	  
Programme	  /Education:	  Master’s	  in	  Biotechnology	  
Place	  of	  publication:	  Uppsala	  
Year	  of	  publication:	  2012	  
Online	  publication:	  http://stud.epsilon.slu.se	  
Keywords:	  Alzheimer’s disease, proteomics, amyloid-β oligomers, size exclusion 
chromatography.  
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  The	  Faculty	  of	  Natural	  resources	  and	  Agricultural	  sciences	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Department	  of	  Molecular	  Biology	  
	  
	  
3	  
	  
Abstract: 
The prime toxic species that causes Alzheimer’s disease is believed to be oligomeric 
aggregates of the amyloid β peptide (Aβ). The major aim of the work was to develop methods 
to study which proteins in human plasma that interacts with oligomeric neurotoxic forms of 
Aβ. The interactions of Aβ with human biological fluid proteins are important for drug 
discovery efforts against Alzheimer’s disease but still not very well explored. Stable peptide 
oligomers were formed by a special variant of Aβ (called Aβ42cc). The co-elution of Aβ42cc 
oligomers with human blood serum was carried out using size exclusion chromatography 
(SEC). The eluted fractions were analyzed by SDS-PAGE but no strong interaction between 
Aβ oligomers and blood serum proteins could be observed. 
 
Key words: Alzheimer’s disease, proteomics, amyloid-β oligomers, size exclusion 
chromatography.  
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Popular Science Summary 
The most common neurodegenerative disorder of aging is Alzheimer’s disease. Alzheimer’s 
disease is characterized by the large extracellular deposits of senile plaques in the brain that 
consists of aggregated fibrillar amyloid β peptides. Amyloid β peptides are 39-43 amino acids 
in length and produced by the cleavage of amyloid precursor protein (APP) by γ-secretase and 
β-secretase enzymes. The biochemistry of amyloid β oligomers has been a fascinating area of 
research for therapeutic inventions. The aim of my thesis was to develop methods to study 
which proteins in human blood serum that interacts with oligomeric neurotoxic forms of the 
amyloid β peptide. One part of my thesis was the production of recombinant Aβ42cc in E.coli 
and purification of Aβ oligomers using separation techniques. In the next step, the thesis 
focused on developing methods to capture binding proteins from human blood serum using 
Aβ42cc oligomers. For this purpose, co-elution of Aβ42cc oligomers with human blood 
serum was investigated using size exclusion chromatography as a method for interaction 
studies of human blood serum proteins with Aβ42cc oligomers. We know in SEC large size 
molecules elute earlier than the smaller size molecules. It was expected that the proteins that 
interacts with Aβ42cc oligomers will elute earlier than the non-interacting proteins. Those 
fractions were further analyzed by using SDS-PAGE to separate different components. From 
the gel it was observed that there was no strong interaction of Aβ42cc oligomers with human 
serum proteins. 
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Aim: 
 
The aim of this study is to develop methods to study which proteins in human plasma that 
interacts with oligomeric neurotoxic forms of the amyloid β (Aβ) peptide 
 
It investigates: 
 
• Size exclusion chromatography of the mixtures of special variant of Aβ (Aβcc) 
oligomers and plasma. 
• Analysis of the eluted fractions by gel electrophoresis (SDS-PAGE). 
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Introduction: 
Alzheimer’s disease is an age-related progressive degenerative disorder. Alzheimer’s disease 
is characterized by the loss of neurons and synapses from the brain and accumulation of senile 
plaques and neurofibrillary tangles (1). Amyloid β peptide (Aβ) is a 39-43 amino acid 
residues long cleavage product of amyloid precursor protein (APP) and is the main 
component of senile plaques. APP is a single-pass trans-membrane protein with 695-770 
amino acids, transported from endoplasmic reticulum to the cell surface through a secretary 
pathway (2) and expressed at high levels in the brain and metabolized in a rapid and highly 
complex fashion by a series of sequential proteases. APP is cleaved by membrane associated γ 
and β-secretases which generates peptides with different sizes like Aβ(1-40) and Aβ(1-42). 
Aβ(1-42) has increased hydrophobicity and tendency to aggregate so, it is considered more 
neurotoxic than Aβ(1-40) (3). Synthetic Aβ spontaneously aggregates into β-sheet rich fibrils. 
The insoluble fibrillar aggregates were reported to be neurotoxic in vivo and in vitro so that it 
was believed that fibrils are responsible for neurodegeneration in Alzheimer’s disease (4). 
In some studies ranges of the assemblies, from dimers to 24 mers or even higher molecular 
weights, of Aβ are reported (5, 6, and 7). Although some studies strongly supports that such 
soluble Aβ oligomers are the causative agent of Alzheimer’s disease, the biological and 
structural characteristics of Aβ oligomers and their formation mechanism is still unclear.  
Alzheimer’s disease is still incurable and the mortality rate is increasing rapidly. It is very 
important to learn more about the molecular mechanism of Alzheimer’s disease to treat and 
prevent Alzheimer’s disease in the future. To develop effective therapeutics based on 
interactions between Aβ and human blood serum proteins, increased understanding of the Aβ 
binding ligands is necessary. 
 
History of Alzheimer’s disease:  
In1901, a patient named Auguste D, 51 years of age was suffering from cognitive and 
language deficits, auditory hallucinations, delusions, paranoia aggressive behavior. Her 
condition was studied by a doctor, Alois Alzheimer. In 1906 Auguste died. In November of 
the same year Alzheimer presented Auguste’s case at a psychiatry meeting and published his 
talk in 1907. Today this degenerative brain disease bears his name.  
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Among of the two distinct pathologies one is neurofibrillary tangles that was summarized by 
Alzheimer as intracellular aggregates later it was observed that it composed of 
hyperphosphorylated and cleaved form of the microtubule associated protein tau. Another one 
is miliary foci. The miliary foci were a dystrophic neuronal process that surrounds a special 
substance in the cortex (8).  After isolation and purification it was confirmed that special 
substance was a 4.2 kDa protein and 40-42 amino acids long and it is a cleavage product of 
long precursor (9). Their prediction was verified by cloning APP in 1987 (10).  The peptide 
that was isolated by Glenner and Wong is known as Aβ peptide. 
 In 2001, the first Alzheimer disease vaccine trial was conducted in U.S. and Europe. There 
were serious side effects and it was stopped later. In 2002, a new drug called NMDA receptor 
blocker was developed. Some currently used treatments include cholinergic pathway of 
degeneration, anti-oxidants, anti-inflammatory drugs and estrogen. 
AD is still incurable and Alzheimer’s disease today affecting more than 26 million peoples all 
over the world with projections of a fourfold increase by 2050 (11).  
 
Pathology of Alzheimer’s disease: 
In Alzheimer’s disease, Aβ that is expressed normally and ubiquitously throughout the life, 
forms fibrils that deposits in the brain as senile plaques. This senile plaques and 
neurofibrillary tangles, which are built by hyper phosphorylated tau protein, are the 
pathological hallmarks of Alzheimer’s disease (12 and 13). 
The power house of cell is known as mitochondria that meets the energy demand of the cell. 
In case of some defects in mitochondria it cannot supply energy to the cell but it can damage 
the cell by producing reactive oxygen species (ROS), which leads to cellular oxidative stress 
(14). Aβ can induce the generation of ROS and production of apoptogenic proteins and thus 
can promote the toxicity to neurons (15, 16). 
In neurons, the microtubule sensitizing protein is tau. An inflammatory response can be 
triggered by hyperphosphorylated tau proteins. Hyperphosphorylated tau proteins can disrupt 
the normal microtubule binding which leads to the loss of axons and defective neuronal 
communication. Later this can lead to the neuronal loss (17, 18). 
For the nucleation of Aβ fibrils two mechanisms have been proposed. The first one involves 
the self-assembly of the Aβ monomers that undergoes a conformational change to become the 
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fibril nucleus where the second one involves the alternative pathway of heterogeneous 
nucleation that results from the outgrowth of fibrils from Aβ seeds (19). 
A heated debate for the last 20 years has been ongoing whether tau protein or Aβ is the initial 
event in Alzheimer’s disease. As this thesis is mainly about Aβ oliomers so, from now only 
Aβ will be focused on. 
 
Processing of APP: 
APP is strongly linked with the development of Alzheimer’s disease. The APP gene located 
on chromosome 21. APP is proteolytically cleaved by alpha (α), beta (β) and gamma (γ) 
secretases (20). The proteolytic processing of APP can be either via amyloidogenic or non-
amyloidogenic pathway (shown in fig 1). 
The non amyloidogenic pathway involves the sequential cleavage by α-secretase within the 
amyloid peptide domain that is later cleaved by γ-secretase and produces secretary APP 
(sAPP) α segment and the membrane bound C- α-terminal fragment (α-CTF) is cleaved by γ-
secretase and produces P3, a truncated non-amyloidogenic peptide. On the other hand the 
amyloidogenic pathway involves the cleavage by β-secretase at the C-terminus and releases          
sAPP β and a membrane bound Cβ-terminal fragment (β-CTF). Later the multimeric γ-
secretase cleaves β-CTF at different cleavage sites producing amyloidogenic Aβ peptides of 
different sizes. The main variants are Aβ(1-40) and Aβ(1-42) containing 40 and 42 amino 
acids respectively. 
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Fig.1: Processing of APP. 
 
 
Aβ42cc- ZAβ3 complex: 
Aβ42cc is an engineered variant of Aβ(1-42) that enables the isolation of stable oligomers. 
Ala21 and Ala30 used for the purpose of protein engineering, as their β-carbons are located 
on opposite β-strands at a distance of 4.2 Å from each other. A Cys21/30 disulfide 
accommodated with favorable conformational energy and without perturbing the hairpin 
structure where the 12 backbone hydrogen bond is predicted to form in Aβcc (21).  
 It can be produced in E.coli cells by co-expression with ZAβ3 affibody. ZAβ3 co-expression 
also permits the recombinant production of Aβ (1-42) (3). 
 ZAβ3 is a di-sulfide-linked homodimer of affibody subunits (22). Affibody ZAβ3 binds to the 
central C-terminal part of the Aβ (fig 2) that then adopts a β-hairpin conformation.  
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Fig.2: Structural representation of Aβ-ZAβ3 complex. Here the red colored structure 
represents the Aβ peptide and the blue colored structure represents ZAβ3 affibody. (Fig source: 
PDB accession no: 20TK, (22), kindly provided by Christofer Lendel).  
 
  
Blood serum: 
In blood, the serum contains all proteins that are not involved in blood clotting (coagulation) 
and all the electrolytes, hormones and any exogenous substances. In clinical testing serum is 
the preferred specimen. Blood proteins are known as plasma proteins or serum proteins. 
Blood proteins have several functions including circulation of transport molecules for lipids, 
hormones, vitamins and metals, regulation of cellular activity and functioning and in the 
immune system. Blood contains about 3.5-5.0 g/dl albumin (normal level), 60% of total 
volume. Immunoglobulin contributes about 18% (1.0-1.5 g/dl, normal level), fibrinogen 
contributes about 4% (0.2-0.45 g/dl) and other regulatory proteins contains <1% of total 
volume. Other types of blood proteins include prealbumin alpha1 antitrypsin, alpha 1 acid 
glycoprotein, alpha 1 fetoprotein, haptoglobin, alpha 2 macroglobulin, feroplasmin 
transferring C3/C4 beta 2 micro globulin, beta lipoprotein, gamma globulin proteins, C-
reactive protein (CRP). 
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The understanding of human serum protein interaction with Aβ oligomers is very important 
for novel therapeutic inventions. As a part of development of methods to identify the serum 
protein interaction with Aβ oligomers, I have introduced size exclusion chromatography 
(SEC) to separate the proteins according to their sizes where the proteins interacting with the 
large Aβ oligomers proteins were expected to elute earlier than the non-interacting proteins. 
This thesis report will discuss SEC as a method to capture binding proteins from biological 
fluids (blood serum) using Aβ cc oligomers.  
 
Techniques used in this project: 
Immobilized metal ion affinity chromatography : 
Immobilized metal ion affinity chromatography (IMAC) is based on the binding between 
proteins and metal ions. Because of different amino acid compositions, proteins have different 
affinities towards different metal ions. Proteins can also be engineered to contain a poly-
histidine tail that can act as a ligand towards metal ions.  
A mixture of proteins can be separated according to their interacting abilities towards metal 
ions. Proteins with more histidine residues bind more tightly than those proteins with fewer 
histidine residues. Several types of metal ion affinity chromatography techniques (for 
example, Co, Cd, Fe, Ni, Zn) have been developed to separate proteins.  
 
Size exclusion Chromatography: 
In SEC the molecules are separated based on size (23). It is also called molecular exclusion or 
gel permeation chromatography. When an aqueous solution is used to transport the sample 
through the column then it is called gel-filtration chromatography. Protein mixtures are 
applied to a gel filtration column containing chromatographic matrix where stationery phase 
consists of porous beads with a defined set of pore sizes. Proteins are said to be included if 
they are small enough to fit inside the pore of beads and have the access to both the stationary 
inside the beads and the mobile phase between beads and elute last in a gel filtration 
separation. Proteins are said to be excluded if they are too large to fit inside of any pore. 
Those larger proteins only have the access to the mobile phase and elute first. Proteins with 
intermediate size partially can fit inside but not in all of the pores of beads and elute between 
the large (excluded) and small (totally included) proteins. The small proteins that enters inside 
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the beads elute at last. One of the Advantages of this method is that it separates large 
molecules from the small molecules with a minimal volume of elute (24). 
The main application of the gel-filtration chromatography is the fractionation of the proteins 
and other water soluble polymers. As the sample do not interact with the stationery phase 
there is no sample loss. This technique can be combined with other techniques to further 
separate molecules according to other characteristics like acidity, basicity, charge and affinity 
for certain compounds. 
The technique was invented by Grant Henry Lathe and Colin R Ruthven, working at Queen 
Charlotte’s hospital, London (25, 26). Ruthven and Lathe introduced starch gels as the matrix, 
Jerker Porath and Per Flodin later introduced dextran gels (27). Other gels with size 
fractionation properties including agarose and polyacrylamide. In 1964, J.C. Moore of the 
Dow chemical company published his work on the preparation of gel permeation 
chromatography columns based on cross-linked polystyrene with controlled pore size (28). 
To perform a separation gel filtration medium is packed into a column to form a packed bed. 
The medium is the porous matrix in the form of spherical particles that have been chosen for 
their chemical and physical stability and inertness. The packed beds are equilibrated by using 
buffer. Buffer fills the pores and the space between the matrix particles. The particles of 
different sizes will elute through a stationery phase at different rates. All the particles are 
loaded simultaneously or near-simultaneously, particles of the same size should elute 
together. 
The apparatus that is used for the separation of molecules in SEC is called column.  A SEC 
column consists of hollow tube tightly packed with extremely small porous polymer beads 
designed to have pores of different sizes. To maximize the resolution the proper column 
packing is very important. An over packed column can collapse the pores in the beds and thus 
results the loss of resolution. An under packed column can reduce the relative surface area of 
the stationery phase that are accessible to smaller species and results those species spending 
less time trapped in pores. 
The eluent is collected in constant volumes that are known as fractions. The collected 
fractions are then examined by spectroscopic techniques to determine the concentration of the 
particles eluted. Refractive index and ultraviolet absorbance are commonly used to examine 
eluates. 
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Experimental parameters of size exclusion chromatography:  
Sample:  
The viscosity of sample should not be so large to cause hydrodynamic instability. The pH, 
ionic strength and composition are not significant as long as they do not affect the sizes or the 
stability of the molecules to be separated.  
Column: 
The way of packing the column is the most important characteristic of gel filtration column. 
In evenly packed column, the sample zone is not unnecessarily broadened when it passes 
down the column and good results are obtained. Good results cannot be obtained with 
unevenly packed column. The length of the column is significant because it affect both the 
resolution and the elution time. Resolution is proportional to the square root of column length 
and elution time is proportional to column length 
Running conditions: 
The rate of eluent flow through affects both the speed at which the separation is obtained and 
the resolution which can be achieved. Lower flow rate gives better resolution at least for large 
molecules (29). In the form of an elution diagram the results of gel filtration are expressed. It 
shows the variation of solute concentration in the eluate with the volume of eluent passed 
through the column. Continuous detection using a UV monitor gives an immediate permanent 
record, a chromatogram when working with protein and nucleic acid. From this diagram the 
elution volume (Ve) can be defined. 
SDS-PAGE: 
Electrophoresis is a technique where the macromolecules are separated by applying an 
electric field. SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) is 
commonly used method for separating proteins where the polyacrylamide gel is used as a 
support medium and SDS is used to denature the proteins. SDS is an anionic detergent that 
gives the molecules a negative charge over a wide pH range. The amounts of SDS that bind to 
the polypeptide chains proportionally to it’s relative molecular mass when the complex 
protein structures are destroyed by SDS. These structures are attracted towards the anode. 
Because of the presence of SDS, proteins are separated according to their sizes. 
Polyacrylamide gels restrains larger molecules from migrating as fast as smaller molecules. 
Relative molecular masses, relative abundance of major protein in a sample can be estimated 
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by SDS-PAGE. Moreover it is also possible to monitor the purity of protein, fractionation 
progress and the efficiency of the purification procedure by SDS-PAGE. 
 
Silver staining: 
Silver staining is a procedure of detecting proteins after electrophoretic separation on 
polyacrylamide gels. It provides excellent sensitivity (in the low nanogram range) using very 
simple and cheap equipment and chemicals. Silver staining is compatible with downstream 
processing such as mass spectrometry analysis after protein digestion. The sequential phases 
of silver staining are protein fixation, then sensitization, then silver impregnation and finally 
image development. Switzer et al., introduced silver staining in 1979 (30). Silver staining 
provides a very sensitive tool for protein visualization with a detection level of 0.3-10 ng (31). 
The basic mechanism of silver staining  is  protein detection based on the binding of silver 
ions to the amino acid side chains, primarily the sulfhydryl and carboxyl groups of protein 
(31, 32, 33, 34), that is followed by reduction to free metallic silver (35, 36). Based on the 
reduction the protein bands are visualized as spots. The image of protein distribution in the 
gel is visualized as the difference in the oxidation-reduction potential between the gel’s area 
occupied by the proteins and the free adjacent sides. Silver amine or alkaline methods, and 
silver nitrate or acidic methods are the two general silver staining protocols (37). The silver 
amine or alkaline methods usually have lower background and are more sensitive but the 
problem is that it requires longer procedures. On the other hand acidic procedures are faster 
and less sensitive than the alkaline methods. Several silver staining procedures have been 
developed with different advantages regarding timing, sensitivity, cost and compatibility with 
other analytical methods.  
 
Materials and Methods: 
Expression: 
Aβ42cc-ZAβ3 was expressed in Escherichia coli origami B cells from plasmid pACYDUet-1 
coding for Aβ42cc and the affibody ZAβ3 under separate promoters. In addition to ZAβ3 
affibody sequence, the construct contained an N-terminal (His)6 tag. Expression vector 
pACYCDuet is designed for the double cistronic coexpression of two target genes and 
contains two multiple cloning sites (MCS) and each of the MCS is proceeded by a T7 
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promoter/lac operator and a ribosome binding site. Expression vector contained the elements 
in the following order:  T7 promoter-1- MAβ - T7 promoter-2- (His)6 z Aβ3- T7 terminator. 
Thus Aβcc was produced in E.coli by co-expression with ZAβ3 complex. The cells are resistant 
to chloramphenicol (14). Cells were grown in overnight pre-culture at 37	   °C and 120 rpm 
agitation. Overnight culture contained TB medium, potassium phosphate buffer and 
antibiotics (34 mg/l chloramphenicol, 12.5 mg/l tetracycline and 15 mg/l kanamycin). 75 ml 
of overnight culture was added per 0.9 l TB together with the antibiotics (in case of 75 ml of 
1X TB medium, 8.3 ml of 0.89 M (0.17 M potassium di-hydrogen phosphate and 0.72 M di-
potassium hydrogen phosphate) potassium phosphate salt (10 X concentrate) and 83	  µl of 
each of three antibiotics (kanamycin 15 g/l, tetracycline 12.5 g /l, chloramphenicol 34 g /l) in 
a flask. Each 1 l of TB medium contains 12 g tryptone, 24 g yeast extract, and 4 ml glycerol in 
water solution. The main culture was incubated at 37 °C with agitation (120 rpm). The OD 
value at 600 nm was monitored using UV spectrophotometer (Shimadzu). Protein expression 
was induced at OD(600 nm)=0.6-0.8 with 75 µl of 1 M IPTG (isopropyl β-D-1-
thiogalactopyranoside). IPTG is a mimic of lactose and will induce the expression of genes 
under the control of lac Z promoter. Cells were incubated for 4 hours after induction with 
IPTG. Cells were harvested by 20 min centrifugation at 4500 rpm at 4 °C. The cell pellet from 
1 l culture was resuspended in 30 ml 100 mM tris-hydrochloride; 500 mM sodium chloride 
plus 0.25-0.5 tablet of complete protease inhibitors cocktail (Roche). The resuspended cells 
were transferred into a 50 ml conical bottom falcon tube and kept at -20 °C. 
Cell lysis:  
Cell pellets were completely thawed and kept on ice. The sample was sonicated on ice bath 
(ice plus some water for good heat transfer). It was sonicated using Vibra cell T.M. (CiAB 
Chemical instruments AB) at 75% amplitude in pulses (5 s ON and 9.9 s OFF) with a total 
sonication time of 2.5 min. Insoluble materials were removed by centrifugation of the cell 
lysates for 40 min at 18000 rpm at 4 °C (Sorvall centrifuge, ss-34 rotor). The supernatant was 
filtered through 0.45 µm and then 0.2 µm filter. 
IMAC:  
The first step of protein purification was achieved by IMAC employing an Äkta purifier. 
After recharging the IMAC column with 0.1 M nickel sulfate salt the filtered protein sample 
was loaded onto 5 ml Hi Trap IMAC HP Ni-NTA column (GE Healthcare). IMAC was 
carried out in 20 mM tris-hydrochloride, pH 8.0; 500 mM sodium chloride (buffer A) and 20 
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mM tris-hydrochloride, pH 8.0; 500 mM sodium chloride; 300 mM imidazole (buffer B). 
After loading the lysate, the column was washed with 4% buffer B for 3-4 min, then 100% of 
buffer B for 10 min to elute the complex. The fractions supposed to contain Aβ42cc-ZAβ3 
complex (3) were collected and pooled and EDTA was added to a final concentration of 5 
mM. EDTA is used to prevent metal ion binding with the protein complex.  
The IMAC fractions that are supposed to contain Aβ42cc-ZAβ3 complex was concentrated on 
5 kDa cut off vivaspin to OD=3.9 AU at 280 nm measured using Nanodrop 1000 
spectrophotometer (Thermo scientific). 
SEC:  
The concentrated eluted fractions from IMAC were loaded in 1.5-2 ml samples onto Superdex 
75 10/300 column equilibrated with 20 mM tris-hydrochloride, pH 8.0; 200 mM sodium 
chloride at 0.7-0.9 ml/min flow rate. After elution, the fractions containing Aβ42cc-ZAβ3 
(known elution volume as the purification was carried out according to an established 
protocol) were concentrated on 5 kDa cut-off vivaspin to OD=4.5 AU at 280 nm measured 
using Nanodrop 1000 spectrophotometer (Thermo scientific). 
Denatured IMAC:  
From SEC, 1-5 ml of concentrated sample was diluted in 25 ml of 7 M guanidinium 
hydrochloride (GdnHCl) (>99% pure sigma), 0.5 M sodium chloride, 0.1 M tris-
hydrochloride; pH 8.0, and kept on a shaker at room temperature until the GdnHCl dissolved. 
The tube containing the sample was then kept on a titling table for 30 min and then the protein 
sample was filtered using 0.2 µm filter. Then denatured IMAC was run. Sample was loaded at 
0.5 ml/min onto a 5 ml Hi Trap IMAC HP Ni-NTA column (GE Healthcare) equilibrated with 
20 mM tris-hydrochloride; pH 8.0; 7 M GdnHCl. Most of the Aβ42cc elutes with the flow 
through but some binds to the column (as judged by SDS-PAGE later). The flow through was 
collected and the column was washed with an imidazole gradient of 0-40 mM for 30 min, 
which was followed, by a gradient to 400 mM imidazole for 5 min then affibody ZAβ3 
containing fractions (as judged by SDS-PAGE later) elutes. 
SDS-PAGE:  
Fractions that are supposed to contain Aβ42cc and ZAβ3 were collected and 100 µl of sample 
from each fraction were dialyzed against 7 M urea overnight. Then the dialyzed fractions 
were prepared for SDS-PAGE; 10 µl of loading buffer (containing 4 M urea, 15% glycerol, 
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10% SDS and 15 mM tris (2-carboxyethyl) phosphine) and 20 µl of sample were mixed. For 
further denaturation the peptides the sample was kept on 100 °C for 5 min. Then SDS-PAGE 
was run using 0.1 M tris as anode buffer and tricine as cathode buffer. About 15 µl of sample 
was loaded with Hamilton syringe. The syringe was washed with water between samples. 
Molecular size marker (5 µl) was loaded in one or two wells. The gel was run at 130-140 V 
until the blue bands reached the bottom of the gel. The gel was then removed and placed in 
fixation solution. 
Silver staining: 
After the SDS-PAGE the gel was removed from the cassette and placed into a tray containing 
appropriate volume of fixation solution (50% ethanol, 12% acetic acid, 0.05% formalin). 
Fixation solution was added to restrict protein movement from the gel matrix. The gel was put 
on titling table for 1 hour. The fixation solution was discarded and the gel was washed with 
20% ethanol for 20 min. The washing solution was changed 3 times during this time. The 
ethanol solution was discarded and sensitizing solution (0.02% (w/v) sodium thiosulphate) 
was added and incubated for 2 min. The sensitizing solution was discarded and the gel was 
washed with deionized water. After discarding the water, cold silver staining solution (0.2% 
(w/v) silver nitrate, 0.76% formalin), was added and the gel was kept in it for 20 min. After 
staining was done the gel was washed with deionized water for 60 s. The gel was rinsed with 
the developing solution. New portion of developing solution was added and the protein bands 
were developed by incubating the gel in 300 ml of developing solution (6% (w/v) sodium 
carbonate, 0.0004% (w/v) sodium thiosulfate, 0.05% formalin) for 2-5 min. The reduction 
reaction was stopped by adding 50 ml of terminating solution (12% acetic acid).  
Production of Aβ42cc oligomers: 
Aβ containing fractions from denatured IMAC were concentrated using 3 kDa cut-off to a 
final concentration of OD(280 nm)=1.3 AU. The sample was dialyzed against 20 mM sodium 
phosphate pH 7.2; 50 mM sodium chloride with 5 mM EDTA acid overnight..  EDTA has the 
ability to sequester metal ions. Aβ oligomers formed spontaneously during dialysis against 
sodium phosphate at pH 7.2. Then the oligomeric solution was heated at 60 °C for 10 min in 
water bath and again dilaysed to remove EDTA (same buffer). The peptide concentration was 
0.49 mM. Finally the sample was frozen in liquid nitrogen and stored in -20 °C freezer.  
 
21	  
	  
Blood serum: 
The blood serum (normal human serum, single donor) in our experiment was purchased from 
3H biochemical AB, Uppsala, Sweden. Prior using in the experiments the serum sample was 
stored in -20°C. 
Columns used in this project: 
Sephacryl S-100 HR (GE Healthcare) 
Superose 12HR 10/30 (GE Healthcare) 
Superdex 200 (GE Healthcare) 
Superdex 75 10/300 (GE Healthcare) 
 
Selection of buffer solution for size exclusion chromatography of Aβ oligomers and 
blood serum: 
Three different buffer compositions like 20 mM sodium phosphate pH 7.4; 50 mM sodium 
chloride, 20 mM sodium phosphate pH 7.4; 100 mM sodium chloride and 20 mM sodium 
phosphate pH 7.4; 150 mM sodium chloride were used in Superdex 200 HR 10/300 gel 
filtration experiments with Aβ oligomers and blood serum. High quality chemicals and water 
were used for the preparation of buffer and filtered through 0.2 µM filter. Buffer solution was 
degassed as it was filtered under vacuum condition. Aβcc oligomeric sample (absorbance at 
280 nm = 0.6 AU) and of blood serum sample (absorbance at 280 nm = 43.9 AU) were used 
for buffer test. 50 µl of Aβ oligomeric sample and 25 µl blood serum was loaded on to 
Superdex 200 HR 10/300 gel filtration columns.  
 
Selection of gel filtration column with best resolution: 
Resolution: 
The resolution is defined as the degree of separation between peaks of a gel filtration 
separation. The inevitable broadening of peaks during the chromatographic process can make 
it difficult to discern two consecutive peaks in a chromatogram from each other. Resolution is 
a function of selectivity of the medium and the efficiency of the medium to produce narrow 
peak (minimal peak broadening). The resolution (Rs) between two peaks in a chromatogram 
is given by:  
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                    Rs =   2 ∆Z / (WA+ WB) 
                         = 2 [(tR) A- (tR) B] / (WA+ WB)                 (1) 
Here in equation 1, the separation between peaks A and B is indicated by ∆Z,  WA and WB are 
the width at the base of peaks A and B respectively, and (tR) A and (tR) B are the retention time 
of peak A and B respectively. Acceptable resolution is on the order of Rs = 1.0 and baseline 
separation between two peaks requires Rs > 1.5. As mentioned earlier four different types of 
columns were used to study the resolution of Aβ oligomers and blood serum. 
Sephacryl S-100:  
The column was equilibrated with the running buffer (20 mM sodium phosphate; pH 7.4; 150 
mM sodium chloride). First, 100 µl of Aβ oligomers (absorbance at 280 nm = 0.6 AU) were 
loaded. After the elution of all of the loaded samples at a flow rate of 0.6 ml/min the column 
was equilibrated again. Then, 50 µl of filtered blood serum (absorbance at 280 nm = 43.9 AU) 
was loaded. 
Superose 12 HR 10/30 
At first, the column was equilibrated with the running buffer (20 mM sodium phosphate; pH 
7.4; 150 mM sodium chloride). Then 25 µl of blood serum was loaded with 20 mM sodium 
phosphate; pH 7.4; 150 mM sodium chloride at a flow rate of 0.5 ml/min. Then, 50 µl of 
Aβcc oligomers were loaded using the same buffer and same flow rate after equilibrating the 
column again. 
Superdex 75 HR 10/300 GL and superdex 200 HR 10/300 GL: 
25 µl of blood serum was loaded with 20 mM sodium phosphate; pH 7.4; 150 mM sodium 
chloride at a flow rate of 0.5 ml/min. Then, 50 µl of Aβcc oligomers were loaded using the 
same buffer and same flow rate after equilibrating the column again. 
Optimization of the experimental condition using different flow rates:  
The condition was optimized considering the flow rate in Superdex 200 HR 10/300 (0.25-0.75 
ml/min) and the maximum recommended flow rate (1 ml/min). 
Different flow rates were applied in Superdex 200 HR 10/300 gel filtration column with Aβ 
oligomers and blood serum samples separately and the resolution of the separation was 
observed. First 0.1 ml/min flow rate was applied to the column and the resolution of the 
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separation was monitored. Similarly, flow rate 0.2 ml/min, 0.3 ml/min, 0.4 ml/min and 0.5 
ml/min was applied to Superdex 200 HR 10/300 gel filtration chromatography column and the 
resolution of separation was monitored.  
Sample collection for co-elution study: 
After optimizing the conditions, 50 µl of Aβcc oligomeric solution was loaded on Superdex 
200 HR 10/300 column equilibrated with 20 mM sodium phosphate; pH 7.4; 150 mM sodium 
chloride at 0.5 ml/min flow rate and 0.5 ml fractions were collected. Then 25 µl of blood 
serum was loaded with 20 mM sodium phosphate; pH 7.4; 150 mM sodium chloride at 0.5 
ml/min flow rate and 0.5 ml fractions was collected. Fractions after almost 12 ml elution 
volume were pooled and stored in -20 °C. The stored samples (blood serum fractions and Aβ 
oligomers) were mixed at a ratio of 1:1, 1:2 and 1:3 respectively at room temperature. After 
mixing the mix was kept in room temperature for 5, 10, and 15 min respectively before 
loading on to the gel filtration column. 
Another set of samples were prepared on ice. Blood serum fractions and Aβ oligomers were 
mixed in an eppendrorf tube on ice. After preparing the samples of 1:1,1:2 and 1:3 ratio they 
were kept on ice for 5, 10 and 10 min respectively before loading on to the gel filtration 
column. 
Co-elution study of Aβ oligomers with blood serum fraction:  
All of the mixtures of different ratios (prepared in room temperature and on ice) of blood 
serum fractions and Aβ were separately loaded (50 µl) on Superdex 200 HR 10/300 column 
equilibrated with 20 mM sodium phosphate; pH 7.4; 150 mM sodium chloride at 0.5 ml/min 
flow rate and 0.5 ml fractions were collected.  
In the next step of the experiment the fractions that are eluted at the elution volume of Aβ 
oligomers were analyzed by SDS-PAGE. It was expected that the some binding proteins will 
also elute with those fractions. 
After the SDS-PAGE the gel was silver stained following previously described silver staining 
procedure. 
Some problems raised when working with Aβ in size exclusion chromatography because, 
oligomers started to stuck to the column after each run. The problem were solved by washing 
the column using 0.5 M sodium hydroxide after each run.  
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Results and discussions: 
Expression: 
Bacterial cells (E.coli) containing plasmids pACYDuet-1 coding the Aβ1-42cc were cultured 
for the expression of Aβ1-42cc. Table.1 presents the bacterial cell density level before and 
after the addition of IPTG. After getting the absorption of 0.6 AU then IPTG was added. 
Table.1: Protein expression monitored at OD (600 nm). 
After 1 hour of 
incubation  
After 2 hour of 
incubation 
3 hour of incubation after 
the addition of IPTG  
4 hour of incubation after 
the addition of IPTG 
0.37 AU 0.62 AU 1.14 AU 1.23 AU 
 
Purification: 
After IMAC, fractions supposed to contain Aβ42cc-ZAβ3 (3) were collected and concentrated 
up to abs(280 nm) = 3.9 AU. SEC was run with 2 ml of concentrated IMAC fractions 
containing Aβ42cc-ZAβ3 complex. Aβ42cc-ZAβ3 containing fractions were concentrated up to 
abs(280 nm) = 4.5 AU and stored at -20 °C for denaturing IMAC. 
 
                                                                            Elution volume (ml) 
 Fig.3: Immobilized metal ion affinity chromatogram of Aβ42cc-ZAβ3 complex. 
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Fig.3 shows the IMAC purification of the complex. The first peak eluted are the proteins that 
elute with the flow through. In the second peak, proteins that binds weakly to the column are 
eluted with 4% buffer B. Finally the peak after washing with 100% buffer B indicates the 
elution of Aβ42cc-ZAβ3 complex. 
Fractions which were supposed to contain Aβ42cc-ZAβ3 complex were collected and 
concentrated up to abs(280 nm) = 3.9 AU. 
 
 
                                                                            Elution volume (ml) 
Fig.4: Size exclusion chromatogram of Aβ42cc-ZAβ3 complex. 
 
Fig.4 describes two runs of SEC where 2 ml of concentrated samples from IMAC were loaded 
on each run. Large sized molecules elute first and smaller molecules (i.e. supposed to contain 
Aβ42cc-ZAβ3 complex) elutes later. Fractions corresponding to large peak were pooled and 
concentrated using 5 kDa vivaspin cut-off to OD = 4.5 AU at 280 nm. 
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                                                                            Elution volume (ml) 
Fig.5: Denatured immobilized metal ion affinity chromatogram of 42CC Z Aβ3 complex. 
 
The chromatogram in fig.5 represents denatured IMAC. Aβ peptides comes with the flow 
through of 20 mM tris-hydrochloride pH 8.0; 7 M GdnHCl. The imidazole concentration was 
increased to 40 mM during a 20 min gradient and as a result additional Aβcc peptide and 
potentially some ZAβ3 were eluted. Finally, when washed by a gradient of 400 mM imidazole, 
ZAβ3 were eluted. 
It was observed from the chromatogram that fractions A5-A15, B15-B5 elutes with the flow 
through (i.e. the fractions supposed to contain Aβcc because ZAβ3 is still bound to the column) 
after washing with a quick gradient up to 400 mM imidazole buffer, bound ZAβ3 eluted and the 
corresponding fractions are E11-E13. 	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   M A7  A9 A11 B13 B7      M C4  C5   C6             E11 E12 E13 C9            	  
Fig 6: SDS-PAGE gel diagram showing bands of peptides. 
In fig.6 the SDS-PAGE image showed that, fractions A7, A9, A11, B13 and B7 formed single 
bands of about 6.2 kDa molecular weight and also the fractions C4, C5 and C6 formed bands 
of same molecular weight and  this indicates that those fractions contained same peptide 
fractions (Aβ42cc fractions). Fractions E11-E13 formed bands of higher molecular weight 
(about 8.2 kDa) than the other fractions. This indicates that those fractions contained affibody 
(ZAβ3) peptides. 
Production of Aβ42cc oligomers:  
Aβ42cc containing fractions from denatured IMAC were concentrated using 3 kDa cut-off to 
a final concentration of OD 280 nm = 1.3 AU. The sample was dialyzed against 20 mM 
sodium phosphate pH 7.2; 50 mM sodium chloride with 5 mM EDTA. Aβ oligomers (0.49 
mM) formed spontaneously (as the procedure was carried out according to an established 
protocol) during dialysis.  
 
Selection of buffer for size exclusion chromatography of Aβ oligomers and blood serum: 
Buffer of with 20 mM sodium phosphate; pH 7.4;  and 50, 100 or 150 mM sodium chloride, 
were used to test the resolution of separation by loading blood serum and Aβ oligomers on to 
Superdex 200 10/300. After repeating several times at the same condition the obtained 
resolution values did not differ much (the resolution after using first buffer was 4.23 and the 
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resolution after using second buffer was 4.24). The best resolution (4.26) were found using 20 
mM sodium phosphate; pH7.4; 150 mM Sodium chloride.  
Selection of gel filtration column with the best resolution: 
Four different kinds of columns were used to select the best column with better resolution (Rs) 
of separation of Aβ oligomers and blood serum. Sephacryl S-100, Superose 12, Superdex 75 
HR 10/300 and Superdex 200 HR 10/300 showed Rs value 1.76, 1.33, 0.95 and 4.26 
respectively. Acceptable resolution is on the order of Rs= 1.0 and baseline separation between 
two peaks requires Rs > 1.5. So, Superdex 200 HR 10/300 was the best column with respect to 
resolution.  
 
                                                                            Elution volume (ml) 
Fig.7:  Size exclusion chromatography diagram showing the separation of Aβ oligomeric 
sample. 50 µl of sample was loaded on Superdex 200 HR 10/300 GL. 
Fig.7 shows that after loading only Aβ oligomers the peak started to rise after 7.98 ml elution 
volume and started to go down at almost 10 ml of elution volume. After loading only blood 
serum sample (fig.8) it was observed that at about 7 ml of elution volume one small peak was 
rising and goes down at 8.12 ml of elution volume. Then another large peak started to rise at 
11.2 ml of elution volume and goes down at 15.2 ml of elution volume.  
All the fractions after 12 ml of elution volume (no overlap with the peak of Aβcc oligomers as 
they have elution volume of about 8 ml) were pooled and stored for further experiments. The 
protein concentration from the collected fractions was 0.5 AU at 280 nm. 
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                                                                            Elution volume (ml) 
Fig.8: Size exclusion chromatography diagram showing the separation of blood serum 
sample. 25 µl of sample was loaded on Superdex 200 HR 10/300. 
 
 
 
                                                                                              Elution volume (ml) 
Fig 9: Size exclusion chromatogram of Aβ oligomers and blood serum at 280 nm in 
Superdex 200 HR 10/300.  Superdex 200 HR 10/30 showed Rs value 4.26 at 0.5 ml/min flow 
rate. 
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In fig.9 the resolution was calculated from equation.1, where the separation between peaks A 
and B is indicated by ∆Z, retention time of peak A (tRA) is 27.95 ml, retention time of peak B 
(tRB) is 15.52 ml and width of peak A (WA) and  B (WB) are 1.84 ml and 4.16 respectively. 
Optimization of the experimental condition using different flow rates:  
As part of optimization of conditions for SEC separation of Aβ and blood serum, I have tried 
with different flow rates to find the best resolution. I have applied the flow rates 0.1 ml/min, 
0.2 ml/min, 0.3 ml/min, 0.4 ml/min and 0.5 ml/min, in the experiments using Superdex 200 
gel filtration column with 20 mM sodium phosphate; 150 mM sodium chloride; pH 7.4 as 
running buffer using both of Aβ and blood serum separately and found Rs value 2.54, 2.39, 
2.19, 3.44 and 4.26 respectively. Among all of the flow rates, 0.5 ml/min showed the best 
resolution (4.26) for the  separation. 
Aβ oligomers and blood serum fractions (after 12 ml of elution volume, see above) that are 
collected after loading 25 µl of blood serum were mixed in ratios of 1:1, 2:1, and 3:1 
respectively in room temperature and also on ice. All samples with different conditions (room 
temperature or on ice, mixing time) showed almost the same results (shown later with 
chromatograms fig 10-12). 
When loading the samples the concentration of Aβ oligomeric fraction was 0.6 AU 
(absorbance at 280 nm), the concentration of blood serum sample was 43.9 AU as measured 
by absorbance at 280 nm. 
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                                                                                     Volume (ml) 
Fig 10: Elution profile of Aβ oligomers and blood serum fractions (1:1) observed at 280 
nm in Superdex 200 gel filtration column. Sample was mixed at room temperature and kept 
5 min prior loading the sample.  
In fig.10, it was observed that Aβ oligomeric fractions were started to elute at 7.98 ml as the 
elution peak started to rise and the peak goes down at 12.42 ml of elution volume. The 
corresponding fractions were collected for further analysis. 
 
 
                                                                                                      Volume (ml) 
Fig 11: Gel filtration chromatogram of Aβ oligomers and blood serum fractions (ratio 
2:1) observed at 280 nm.  
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Sample shown in fig. 11 was mixed on ice and kept 10 min on ice prior loading the sample. 
Aβ oligomeric fractions were started to elute at 7.41 ml of elution volume and peak goes 
down at 12.78 ml (shown in fig.11). The corresponding fractions were analyzed by SDS-
PAGE. 
 
                                                                                                   Volume (ml) 
Fig 12: Gel filtration chromatogram of Aβ oligomers and blood serum fractions (3:1) 
observed at 280 nm.  
Sample shown in fig. 12 was mixed on ice and kept 15 min on ice prior loading the sample. 
From fig.12, it was observed that Aβ oligomeric fractions were started to elute at 7.90 ml of 
elution volume and absorbance peak goes down at 12.90 ml of elution volume. 
All the fractions that were eluted at the same elution volume as the Aβcc oligomers were 
loaded on SDS-PAGE. Because it was expected that Aβ oligomers will elute with the binding 
proteins. It was observed on gel that only Aβ monomeric, dimeric, trimeric and a weak band 
of blood serum protein was observed.  
The concentrations of the samples before loading on gel (shown in fig.13 and 14) are listed in 
the table 2.  
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Table 2: Protein concentration of samples before loading on the gel. 
Sample Aβ 
fraction 
diluted 
(A8) 
Aβ+serum 
Diluted 
(A5) 
AB+serum 
diluted 
(A6) 
Serum 
fractions 
diluted 
Aβ 
fraction 
conc. 
(A8) 
Aβ+serum 
conc. 
(A5) 
Aβ+serum 
conc. 
(A6) 
serum 
conc. 
Absorption 
at 280 nm 
(AU) 
0.022 0.018 0.016 0.5 0.03 0.023 0.021 1.8  
 
 
   Aβ (dil)              A5                 A6       serum frac.                                    Aβ (con)      A5            A6          serum frac.
 
  1     2       3         4                                      7           8            9             10 
Fig.13: SDS-PAGE gel diagram showing bands of peptides after silver staining (without 
using molecular size marker). Lane 1: diluted Aβ oligomeric fraction that was collected at a 
elution volume of about 8 ml after loading only Aβ oligomers (chromatogram shown in fig.7); 
Lane 2: fraction A5; Lane 3: fraction A6, fractions that were collected after loading mix of Aβ 
oliogomers and blood serum fraction (chromatogram shown in fig.11); Lane 4: blood serum 
fractions that were collected after loading only blood serum at a elution volume of 12 ml 
(chromatogram shown in fig.8) were loaded respectively. On lane 7, 8, 9 and 10 same 
fractions after concentration were loaded.  
From fig. 13 it was observed that on lane 1 and 2 (left) weak Aβcc monomeric bands 
appeared from the Aβcc with blood serum (1:2) diluted fraction. On lane 3, strong Aβcc 
monomeric band was appeared from Aβcc with blood serum (1:2) diluted fraction. No other 
bands of high molecular weight molecules were observed. That means no molecules from 
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blood serum fractions were strongly interacting with Aβcc oligomers. On lane 4, Blood serum 
fractions showed different bands. Corresponding Aβcc fraction (lane 1) and blood serum 
fractions (lane 4) that were collected after 12 ml of elution volume were loaded as control. No 
molecular size marker was loaded.  
In another gel run molecular size marker was used to analyze the fractions. Blood serum 
fractions (chromatogram shown in fig.8) were diluted 1:10. Then the other fractions like A8 
(chromatogram shown in fig.7), A5 and A6 (chromatogram shown in fig.11) were loaded both 
in concentrated and diluted form. A8 fraction supposed to contain Aβ after loading only Aβ 
oligomers. A5 and A6 fractions were collected at the same elution volume of only Aβ 
oligomeric fractions after mixing with blood serum fractions at 2:1 ratio. 
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Fig.14: SDS-PAGE gel diagram showing bands of different peptides. On lane 1 and 15, 2 
µl of 1:10 diluted molecular size marker was loaded. On lane 3 diluted blood serum sample 
was loaded. On lane 5 and 6 concentrated and diluted Aβ fractions (collected after loading 
only 50 µl of Aβ oligomers), on lane 7, 8, 9 and 10 concentrated and diluted fractions from 
1:2 (blood serum: Aβcc oligomers) mix were loaded respectively. 
From fig .14, it was observed that, on lane 9 (concentrated A6 fraction) between 50 kDa and 
75 kDa there have one weak band and this could be a binding protein from blood serum. It 
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might be immunoglobulin (immunoglobulin consist of two light and two heavy chains and the 
molecular weight of heavy chains 51-72 kDa). It seems to correspond to the strongest band in 
the serum sample. The other two bands between 14 to 17 kDa are the dimer and trimer bands 
of Aβcc(22). 
The "smeary" bands between 100-250 kDa in the A6 samples might be Aβ42cc aggregates. 
This would be in agreement with the shift from monomeric Aβ42cc on the other gel (fig 13) 
to the dimers/trimers seen on this gel. So, from the above experiments we could not observe 
any strong interaction between Aβcc oligomers and blood serum proteins. 
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Conclusion: 
In my project, I have tried to develop a method to study the interaction of proteins of human 
blood serum with neurotoxic Aβ oligomers. I have introduced SEC as a part of method 
development but no interaction was observed. The storage condition of Aβcc may be one 
reason as we observed monomeric, dimeric and trimeric bands of Aβcc on gel. Another 
reason may be that there was not sufficient amounts of blood serum proteins present that 
could bind with Aβ. The obtained result suggests that therapeutics based on protein ligand for 
Alzheimer’s disease research needs to introduce other methods. However, SEC is an excellent 
technique to separate the molecules according to their sizes. If the molecules interacted then it 
would be easier to analyze by further experiments like SDS-PAGE and mass spectrometry. 
Moreover, SEC is reliable, easy to handle and not so time consuming technique. In our 
experiment we tried to use different conditions to allow interaction of Aβ and blood serum 
proteins. The general lessons from our condition optimization experiments are that Aβ 
oligomers and blood serum showed the better resolution at a medium flow rate although some 
literature suggested that lower flow rate gives the higher resolution. The reason could be the 
oligomeric nature of Aβ. As no strong interaction was observed, further development of the 
technique using wide range of column designs, lengths, blood serum proteins with proper 
concentration, proper storage and mixing condition of Aβ oligomers with blood serum 
proteins is expected to contribute to our understanding of the Aβ oligomers-blood serum 
protein interaction. 
 
 
 
 
 
 
 
 
 
37	  
	  
Acknowledgements: 
First of all I would like to thank Professor Torleif Härd for giving me the opportunity to this 
project in his group. 
 Big thanks to Anatoly Dubnovisky and Elisabet Wahlberg for their supports during my lab 
work.  
Special thanks to Christofer Lendel, my supervisor. It has been great to working with you. I 
have learned a lot in the lab. Thank you very much for sharing a lot of tips for lab work as 
well as report writing. 
Jerry Ståhlberg, Examiner of my thesis, thank you for revising my thesis. 
Mallikarjun Gupta, opponent, thank you for correcting my thesis, being my opponent and a 
friend. 
And finally, big thanks to my family who always supported me during my studies.  
 
 
 
 
 
 
 
 
 
 
 
 
38	  
	  
References: 
1. Zako T. and Sakano M. (2010) Amyloid oligomers: Formation and toxicity of Aβ 
oligomers. FEBS J, 277, 1348-1358. 
2. Walter J., Kaether C., Steiner H. and Haass C. (2001) The cell biology of Alzheimer's 
disease: uncovering the secrets of secretases Curr Opin Neurobiol, 11, 585–590. 
3. Macao B, Hoyer W, Sandberg A, Brorsson A, Dobson C.M. and Härd T. (2008) 
Recombinant amyloid beta- peptide production by co-expression with an affibody 
ligand. BMC Biotechnol, 8:82. 
4. Hardy J. A. and Higgins G.A. (1992) AD: the amyloid cascade hyphothesis, Science, 
256, 184-185. 
5. Haass C. and Selkoe D.J. (2007) Soluble protein oligomers in neurodegenaration: 
lesson from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol, 8, 101-112. 
6. Glabe C.G. (2008) Structural classification of toxic amyloid oligomers. J Biol Chem, 
283, 29639-29643. 
7. Roychaudhuri R., Yang. M., Hoshi M.M. and Teplow D.B. (2009) Amyloid beta 
protein assembly and AD. J Biol Chem, 284, 4749-4753. 
8. Alzheimer A., Stelzmann R.A., Schnitzlein H.N. and Murtagh F.R. (1995) An English 
translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der 
Hirnrinde” Clin Anat, 8, 429–431. 
9.  Glenner G.G and Wong C.W (1984) Alzheimer’s disease: initial report of the 
purification and characterization of a novel cerebrovascular amyloid protein. Biochem 
Biophys Res Commun, 120, 885–890.	  
10. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., et al (1987) The 
precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. 
Nature, 325, 733–736. 
11. Brookmeyer R., Johnson E., Ziegler-Graham K. and Arrighi H.M. (2007) Forecasting 
the global burden of Alzheimer’s disease. Alzheimers Dement, 3, 186–191.  
12. Puglielli L., Ellis B.C., Ingano L.A. and Kovacs D.M. (2004) Role of acyl-coenzyme 
A: cholesterol acyltransferase activity in the processing of the amyloid precursor 
protein J Mol Neurosci, 24, 93–96.   
13. Tiraboschi P., Hansen L.A., Thal L.J. and Corey-Bloom J. (2004) The importance of 
neuritic plaques and tangles to the development and evolution of AD. Neurology 62,  
1984–1989. 
39	  
	  
14. Zhu X., Su B., Wang X., Smith M.A. and Perry G. (2007) Causes of oxidative stress in 
Alzheimer disease. Cell Mol Life Sci, 64, 2202–2210. 
15. Colell A., Fernandez A. and Fernandez-Checa J.C. (2009) Mitochondria, cholesterol 
and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg 
Biomembr, 41, 417–423. 
16. Reddy P.H. and Beal M.F. (2008) Amyloid beta, mitochondrial dysfunction and 
synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. 
Trends Mol Med, 14, 45–53. 
17. Johnson G.V. and Stoothoff W.H. (2004) Tau phosphorylation in neuronal cell 
function and dysfunction. J Cell Sci, 117, 5721–5729. 
18. Mandelkow E.M. and Mandelkow E. (1998) Tau in Alzheimer's disease. Trends Cell 
Biol, 8,  425–427 
19. Fraser  P., Darabie  A. and McLaurin  J. (2001) Amyloid- β interaction with 
chondroitin sulfate-derived monosaccharides and disaccharides, J Biol Chem, 276, 
6412-6419. 
20. Thinakaran G. and Koo E.H. (2008) Amyloid precursor protein trafficking, processing, 
and function. J Biol Chem, 283, 29615–29619. 
21. Sandberg A., Luheshi M.L., Söllvander S., Barros P.T., Macao B., Knowles P.J.T., 
Biverstål H., Lendel C., Ekholm-Petterson F., Dubnovitsky A., Lannfelt L., Dobson. 
C.M. and Härd T. (2010). Stabilization of neurotoxic Alzheimer amyloid- β oligomers 
by protein engineering. PNAS, 107, 15595-15600. 
22. Hoyer W., Grönwall C., Jonsson A., Ståhl  S. and Härd T. (2008). Stabilization of a β-
hairpin in monomeric Alzheimer’s amyloid- β peptide inhibits amyloid formation. 
PNAS, 105, 5099-5104. 
23. Paul-Dauphin S., Morgan M.A. and Herod K. (2007) Probing Size Exclusion 
Mechanisms of Complex Hydrocarbon mixtures: The Effect of Altering Eluent 
Compositions. Energy & Fuel 621, 3484-3489.  
24. Skoog D.A. (2006) Principles of Instrumental Analysis, 6th ed.; Thompson 
Brooks/Cole: Belmont, CA. 
25. Lathe G.H. and Ruthven C.R. (1955) The separation of substances on the basis of their 
molecular weights, using columns of starch and water. Biochem J, 60, xxxiv. 
26. Lathe G.H. and Ruthven C.R. (1956). The separation of substances and estimation of 
their relative molecular sizes by the use of columns of starch in water. Biochem J, 62, 
665-674. 
40	  
	  
27. Porath J. and Flodin P. (1959) Gel filtration a method for desalting and group 
separation. Nature, 183. 1657-1659. 
28. Moore J.C. (1964) Gel permeation chromatography. A New Method for Molecular 
Weight Distribution of High Polymers. J Polymer Sci A, 2, 835-843. 
29. Gel Filtration Principles and Methods. GE Healthcare. 
     30. Gromova I, Celis J.E (2006) Protein detection in gels by silver staining: A Procedure 
compitable with Mass-spectrometry. Cell Biology: A Laboratory handbook, 3rd 
edition. 
     31. Switzer R.C. 3rd, Merril  C.R. and Shifrin  S. (1979) A highly sensitive silver stain for 
detecting proteins and peptides in polyacrylamide gels. Anal Biochem, 98, 231-237.   
32. Oakley B.R, Kirsch  D.R., and Morris N.R. (1980) A simplified ultrasensitive silver 
stain for detecting proteins in polyacrylamide gels. Anal Biochem, 105, 361-363. 
    33. Merril C.R., Dunau M.L. and Goldman  D. (1981) A rapid sensitive silver stain for 
polypeptides in polyacrylamide gels. Anal Biochem, 110, 201-207. 
   34. Merril C.R. and Pratt M.E. (1986) A silver stain for the rapid quantitive detection of 
proteins or nucleic acids on membranes or thin layer plates. Anal Biochem, 156, 96-
110. 
   35. Rabilloud T. (1990) Mechanisms of protein silver staining in polyacrylamide gels: a 10-
year synthesis. Electrophoresis, 10, 785-794. 
   36. Rabilloud T. (1999) Silver staining of 2-D electrophoresis gels. Methods Mol Biol, 112, 
297-305. 
   37. Merril C.R. (1990) Silver staining of proteins and DNA. Nature, 343 (6260), 779-80. 
 
